Blarcamesine remains safe and effective while AD is still an unmet need. The EMA encouraged Anavex to go the pathway of full approval. Tutes are now steady increasing. The days of knocking on the CEO are getting shorter. I also added today..All and all seems like very good odds for EMA approval.
Market Data 
Markets 
AI
